Venetoclax has impressive activity in ER+ & BCL-2+ breast cancer (See original publication below) December 7, 2018
Original publication: A Phase Ib dose-escalation & expansion study of the BCL2 inhibitor venetoclax combined with tamoxifen in ER+ & BCL2+ metastatic breast cancer December 7, 2018